Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Slides:

Advertisements

Similar presentations

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Advertisements

Sekeres MA et al. Proc ASH 2015;Abstract 908.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase.

Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy by Caroline Besson, Aicha Goubar, Jean Gabarre, Willy Rozenbaum,

by James O. Armitage, and Dan L. Longo

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Long-term outcome after bone marrow transplantation for severe aplastic anemia by Lionel Ades, Jean-Yves Mary, Marie Robin, Christèle Ferry, Raphael Porcher,

by Sandra Luna-Fineman, Kevin M. Shannon, Susan K

Allogeneic Hematopoietic Cell Transplantation in Patients Age Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous.

Fenaux P et al. Lancet Oncol 2009;10(3):

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Protease inhibitors potentiate chemotherapy-induced neutropenia

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is.

Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith,

Grövdal M et al. Blood 2008;112:Abstract 223.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Long-Term Outcomes of the Mosaic Bioprosthesis

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,

Kaplan-Meier curves for overall survival (OS) probability.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Overall survival by SCT versus observation in first complete remission

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Revised International Prognostic Scoring System for Myelodysplastic Syndromes by Peter L. Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo.

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine by Raphaelle Fanciullino, Laure Farnault, Mélanie.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Stavros V. Konstantinides et al. JACC 2017;69:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion Franck E. Nicolini, Eric Wattel, Anne-Sophie.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial.

Impact of age on clinical risk scores in follicular lymphoma

by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001.

Kaplan-Meier analysis for the cumulative percentage of patients who remained hospitalized according to presence or absence of ARF with or without other.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment by Waleed Ghanima, Bertrand Godeau,

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Cold agglutinin disease

Outcomes in patients with PTCL

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Presentation transcript:

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain Thépot, Bruno Quesnel, Francois Dreyfus, Christian Recher, Eric Wattel, Claude Gardin, Lionel Adès, and Pierre Fenaux Blood Volume 119(25):6172-6173 June 21, 2012 ©2012 by American Society of Hematology

Updated Kaplan-Meier estimates of overall survival (OS) of our previously reported cohort of 282 higher-risk myelodysplastic syndromes (MDS) patients treated with azacitidine, with a median follow-up of 41.3 months. Updated Kaplan-Meier estimates of overall survival (OS) of our previously reported cohort of 282 higher-risk myelodysplastic syndromes (MDS) patients treated with azacitidine, with a median follow-up of 41.3 months. (A) Global cohort (n = 282).1 (B) Cohort according to our risk stratification: low (n = 30, median OS: 32.1 month); intermediate (int; n = 191, median OS: 15.0 months); high (n = 48; median OS: 6.1 month; log-rank test: P < 10−4). Raphael Itzykson et al. Blood 2012;119:6172-6173 ©2012 by American Society of Hematology